| Adalimumab | Infliximab | Ustekinumab | |
|---|---|---|---|
| Lack of efficacy | 27.2% (3/11) | 25% (2/8) | – |
| Adverse reactions | 18.2% (2/11) | 37.5% (3/8) | – |
| Lack of response + adverse reactions | 18.2% (2/11) | 12.5% (1/8) | – |
| Lack of adherence | – | 25% (2/8) | – |
| Good response | 36.4% (4/11) | – | – |
| Other reasons | – | – | 100% (1/1) |